L01XX41 • eribulin • Antineoplastic and immunomodulating agents | Other antineoplastic agents
Eribulin is a chemotherapy medication used in the treatment of certain types of cancer, especially advanced breast cancer or liposarcoma. It works by inhibiting cell division, which stops the growth and multiplication of cancer cells.
Eribulin is administered by intravenous infusion at intervals determined by the oncologist, usually once every few weeks. The dose and frequency of treatment are tailored to each patient, depending on the response to therapy and any associated conditions.
Side effects may include fatigue, nausea, vomiting, decreased blood cell counts, hair loss, or, rarely, severe allergic reactions. Medical monitoring is essential throughout the treatment to manage possible complications.
Eribulin is an important option for patients with advanced cancer, offering the chance to slow disease progression and improve quality of life.
Substance: eribulin
Date of last drug list: 01-04-2026
Commercial code: W70422001
Concentration: 0.44mg / ml
Pharmaceutical form: solution for injection
Quantity: 1
Product type: generic
Price: 517.62 RON
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).
Manufacturer: ONCOMED MANUFACTURING A.S - REPUBLICA CEHA
Holder: EVER VALINJECT GMBH - AUSTRIA
Number: 15522/2024/01
Shelf life: 3 years-after packing for marketing;after the first opening of the bottle-it is used immediately